News Column

Investigators at Tarbiat Modares University Discuss Findings in DNA Vaccines (DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding...

September 10, 2014



Investigators at Tarbiat Modares University Discuss Findings in DNA Vaccines (DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Biotechnology have been published. According to news reporting from Tehran, Iran, by NewsRx journalists, research stated, "Cervical cancer is the second most common cancer among women worldwide and remains a clinical problem despite improvements in early detection and therapy. The human papillomavirus (HPV) type 16 (HPV16)E7 oncoprotein expressed in cervical carcinoma cells are considered as attractive tumor-specific antigen targets for immunotherapy."

The news correspondents obtained a quote from the research from Tarbiat Modares University, "Since the transformation potential of the oncogenes, vaccination based of these oncogenes is not safe. In present study, DNA vaccine expressing the modified variant with mutation in pRb-binding motif of the HPV-16 E7 oncoprotein was generated. A novel modified E7 gene with mutation in LYCYE motif was designed and constructed and the immuno-genicity and antitumor effect of therapeutic DNA vaccines encoding the mutant and wild type of E7 gene were investigated. The L-Y-C-Y-E pRb-binding motif of E7 proteins has been involved in the immortalization and transformation of the host cell. The results showed that the mutant and wild type HPV-16 E7 vectors expressed the desired protein. Furthermore, the immunological mechanism behind mutant E7 DNA vaccine can be attributed at least partially to increased cytotoxic T lymphocyte, accompanied by the up-regulation of Th1-cytokine IFN-gamma and TNF-beta and down-regulation of Th3-cytokine TGF-beta. Immunized mice with mutant plasmid demonstrated significantly stronger cell immune responses and higher levels of tumor protection than wild-type E7 DNA vaccine."

According to the news reporters, the research concluded: "The results exhibit that modified E7 DNA vaccine may be a promising candidate for development of therapeutic vaccine against HPV-16 cancers."

For more information on this research see: DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice. Journal of Virological Methods, 2014;206():12-18. Journal of Virological Methods can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Virological Methods - www.elsevier.com/wps/product/cws_home/506080)

Our news journalists report that additional information may be obtained by contacting A.A. Bahrami, Tarbiat Modares Univ, Fac Med Sci, Dept. of Virol, Tehran, Iran. Additional authors for this research include A. Ghaemi, A. Tabarraei, A. Sajadian, A. Gorji and H. Soleimanjahi (see also Biotechnology).

Keywords for this news article include: Tehran, Iran, Asia, Alphapapillomavirus, Biological Products, Biotechnology, Cancer Vaccines, DNA Research, DNA Tumor Viruses, DNA Vaccines, DNA Viruses, Genetics, Human Papillomavirus 16, Immunization, Medical Devices, Papillomaviridae, Synthetic Vaccines, Vaccination, Vertebrate Viruses

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters